Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
nasal spray
Biotech
Double shot of Vistagen’s anxiety nasal spray misses in ph. 2
Just like with a ph. 3 fail in June, Vistagen highlighted fasedienol's superior performance in a subgroup of patients with very severe social anxiety.
Darren Incorvaia
Aug 6, 2026 10:32am
Vistagen lays off 20% of staff to focus on anxiety candidate
Mar 12, 2026 1:16pm
Nasal spray protects mice from deadly flu
Oct 2, 2024 8:54am
Altamira lays off 25% of staff weeks after allergy spray spinoff
Dec 11, 2023 9:58am
Vistagen stock soars 1,272% on social anxiety spray data
Aug 7, 2023 11:38am
VistaGen's social anxiety nasal spray finds open-label success
Mar 22, 2023 3:36pm